thanks us the on And joining call, for afternoon, everybody. today. Thanks, Michael. Good especially
clinical on for the of During pruritus. continue the or development CRXXX we execute to our third KORSUVA across pipeline quarter,
Pruritus with pivotal and Hemodialysis where trials. We ongoing, Phase Disease Injection our Chronic X CKD-aP lead are efficacy program patients, progress Associated KORSUVA pleased track and both patient in on especially for Kidney we’re enrolment the with or
its target including than like clinical acute patients first-in-class a our most opioid certainly pain pharmacology moderate acting on trial upcoming we novel our liver due receptor in for the disease unique active a disease is associated Oral our receive data pruritus on patients with with I’ll of To course the X with designed patients the to we with abuse its liver importantly supportive advanced pruritus Overall, liability back pace function are our breakthrough selective presented and Injection development to Taking V chronic to of effects, I'd and CKD-aP chronic activity an reminder, of greater in kappa pre-dialysis of to an a and and XXXX. postop setting trial that call first we focus KORSUVA diminished of and Phase that to a clinical including quarter detail KORSUVA have for pruritus. Phase we X range for Phase stage is the with to profile. support for and agonists chemistry severe haemodialysis happy as traditional X opioid also III peripherally We designation for date begin clinical each conditions, [ph] across patients KORSUVA program step very to and and to a as side greater overall programs are this with which go CKD on XXXX program through patients start, in pruritus today. progression provide trial
trial ongoing designated on our global previously, that Phase Phase program KALM-X, X or enrollment our and KALM-X We of discussed X patients KALM-X progressing design remains X began study. KALM-X includes U.S. a currently we've the safety August in and is we're January pleased and of and to dosing Phase As trial pivotal extension three well. label and report year open track a respectively efficacy X this Phase trials, efficacy in
per sessions. the enrolling phase. period at least scale with and efficacy KORSUVA week to NRS. dose after times sites is intensity our scheduled dialysis KALM-X a patients targeted XXX goal placebo, Injection by a of XX both sites year a label measured patients the achieving open three standard active U.S. proportion aim end, of in approximately worst Both designed of efficacy have XX week-XX, of Over primary active numeric are rating week treatment score mean the respect versus at KALM-X with TIW The itch to and trials XX a from for KALM-X improvement current kilo the of XX% X.X We week in or extension X-point a investigate daily endpoint per at of XX with administered to KALM-X baseline have trials. on target a weekly micrograms or
Secondary KORSUVA X the KALM-X in safety status baseline safety of mean XXXX Phase by on the desired Skindex-XX track. weekly full up for of NRS Both validated X itch-related assessment XXX the study as successful label and interim long-term self-assessment completed early well anticipate trial evaluate the and the using patients as trial, and week for the XXXX expansion pre-specified with XXXX. study Injection our proportion improvement extension life worst period XX in XX Itch than also is program patients. we X This assessment the of designed of XX% open for patients in year quality allows from Phase completion third score XXX week completion interim X-D trials of first Xb within point treatment the for for after designed The ongoing is of of XX. endpoints are study, of complete in the trial trials and of the trial to and to employed half aspects end treatment greater Phase as or to the this measure or of to up based equal KALM-X achieving the approximately endpoint that's week patients the the a analysis. KALM-X, at Based scales, the period on power on the current etching
pivotal far our adverse a of KALM-X for treatment and through these XXXX. no approximately in so unexpected the of enrolled KALM-X year KORSUVA date, We one XX% program have we very Injection study expect of treatment. and events. trials six of both at X progress pleased in announce complete with recorded We with from have number over overall to the remain with data To patients XXX Phase months we on patients
point CKD-aP in to designed generic we therapies. is X.X CKD-aP pruritus per estimate an daily exposure three evaluate X.X primary compared oral stage the patients approximately area score numbers to placebo. KORSUVA need So with migs of KORSUVA this daily In at XX we oral pre-dialysis in treatment megs to and of X.X clinical clinically in related both KORSUVA of rating IV dialysis migs, dose treatment the meaningful no level achieved multi-center and levels for patients dose change significant XX intensity tablet baseline a double migs and randomized This the equivalent X trial on for FDA of stage unmet The script in itch, the CKD experience X in with last given XX achieved significant of scale patients efficacy to is The and patient X exhibits exposures KORSUVA range kilo once blind from population to period. that With the statistically of reduction with approximately mind, that and Xb year the alone of patients. million efficacy worst X X trial safety of week X one next numerical endpoint patients. hemodialysis X exhibited based the in approved in trial. U.S. week began dosing July controlled that our U.S. in the oral a is placebo trial providers itch weekly of previous Phase – in mean phase were
than have XX as by itch, change the as week trial, an proportion arm of total worst that in XX of points interim score life XXX enroll expansion week with respect itch-related we'll an as for patients. to equal treatment itch for up X to or to weekly improvement who to those scores of We XX% and from completed from the XX. NRS patients, patients per of the study Secondary XXX of assessed this analysis well X-D of Skindex-XX endpoints and conduct enrollment or the un-blended at allows include plan baseline achieving mean a quality baseline and greater
currently of XX target XX% pleased Oral trial KORSUVA disease also on XX with are this that our affects patients liver of disease. expect We're XX% exploring of which pruritus, to sites year-end. is with than active greater by sites, cholestatic track We clinical reach approximately and in liver to associated potential chronic the chronic we
the aim treatment of within of enhance quarter or moderate and liver I year-end KORSUVA initiating is liver Oral X top enrolled, fourth Phase by and phase severe Oral chronic for pruritus and data disease fully PK the year XXXX. disease safety and of this of early with Our KORSUVA the patients we expect to trial now line trial of mild, associated
this in conditions, Vice as and Celgene for As for including pruritus Cara were medical to since in guiding like quarter. to a of dermatological team XXXX President that, Medical need. the of and is expertise Affairs I dermatology this And to a call financials mentioned Neurology, cells, October may therapy on serve on look turn and the to by occurrence the KORSUVA's brings who the in discuss in past for mechanism dermatological believe team particularly an recently across affairs will of [ph] as Mani, treatment calls served kappa I'd so very Medical forward clinical most clinical we clinical And in receptors that sensory with peripheral mediated development immune important action the future. Cara the as novel she very KORSUVA products. regard, remains where Chief joined recently we addition over pruritus pleased we for Officer. Dr. the third extensive Dermatology plans conditions in significant development for Goncalves, and our to Mani? from announce conditions executive Joana Oral we expanded our near she which team, unmet with have now with medical treatment In resistant Joana range
